Eyeing standard of care status in 3rd-line TNBC, Gilead nails down full OK for Trodelvy with a slightly broader label
Even as the FDA gets tough on drugs that miss their mark after accelerated approvals, the agency is still quick to reward the ones that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
